CD8A and COVID-19: To determine whether the inflammatory environment associated with acute disease could impair the induction of SARS-CoV-2–specific CD8+ T cells, we stimulated PBMCs from healthy HLA-A2+ donors in vitro with the influenza virus M1 peptide GILGFVFTL (GIL, residues 58–66) in the presence of serum from uninfected controls or patients with moderate or severe COVID-19.